Abstract
Introduction
Inodilators are the first-choice class of drugs for the treatment of acute heart failure (AHF). Levosimendan is a relatively recent inodilatory agent, presenting superior outcomes in comparison with traditional inotropes.
Methods
An economic evaluation of levosimendan for the treatment of AHF in Italy was performed. In a retrospective study conducted on patients with AHF admitted to a teaching hospital in Rome, two groups were derived from an observational registry: 147 patients treated with levosimendan and 145 treated with dobutamine. Follow-up was at 1 year after treatment. In the reference study looked at in this paper, treatment with levosimendan reduced mean length of stay (LOS) by 1.5 days (P < 0.05). Reduction in the rehospitalization rate was 6.7% (P < 0.05). Mortality rate at 1 month was reduced by 4.8% (P < 0.05).
Results
Based on the reference study, a cost analysis from the hospital perspective was carried out. The incremental cost of treatment with levosimendan (€697) was equivalent to the incremental savings (€694), the latter being obtained from the reduction in LOS (€508) and rehospitalization rate (€186).
Conclusion
Despite the limitations of this study, and even neglecting all nonmonetary health gains as additional outcomes, levosimendan appears to be a competitive alternative compared with dobutamine for the treatment of AHF in the Italian hospital setting.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Rosamond W, Flegal K, Furie K, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25–e146.
Dickstein K, Cohen-Solal A, Filippatos G, et al; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388–2442.
Liao L, Allen LA, Whellan DJ. Economic burden of heart failure in the elderly. Pharmacoeconomics. 2008;26:447–462.
Gigli G, Lispi L, Donati C, et al. Trends in hospitalization for heart failure in Italy 2001–2003. J Cardiovasc Med. 2009;10:367–37
Ministero della Salute. Ricoveri ospedalieri (SDO). Banca dati. 2010. Available at: http://www.salute.gov.it/ricoveriOspedalieri/ricoveriOspedalieri.jsp. Accessed Nov 23 2012.
Stromberg A, Dahlstrom U. Heart failure clinics have decreased mortality and hospitalisation rates in Sweden. Eur Heart J. 2004;25:1368–1369; author reply 1368.
Najafi F, Jamrozik K, Dobson AJ. Understanding the ‘epidemic of heart failure’: a systematic review of trends in determinants of heart failure. Eur J Heart Fail. 2009;11:472–479.
ISTAT. Annuario Statistico Italiano. 2011. Available at: http://www3.istat.it/dati/catalogo/20111216_00/. Accessed Apr 19 2011.
Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J Heart Fail. 2001;3:283–291.
Agenzia nazionale per i servizi sanitari regionali. Ricoveri per acuti in regime ordinario — Tariffe regionali massime. 2008. Available at: http://www.agenas.it/monitoraggio_costi_tariffe/Ricoveri%20Acuti%20Tariffe%20regionali%202008.pdf. Accessed Nov 23 2012.
Marino P, Sutin KM. Acute heart failure syndromes. In: The ICU Book. 3rd edition. Philadelphia: Lippincott Williams & Wilkins; 2006.
Papp Z, Csapo K, Pollesello P, Haikala H, Edes I. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc Drug Rev. 2005;23:71–98.
Papp Z, Edes I, Fruhwald S, et al. Levosimendan: Molecular mechanisms and clinical implications: Consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012;159:82–87.
Landoni G, Biondi-Zoccai G, Greco M, et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med. 2012;40:634–646.
Follath F, Cleland JG, Just H, et al; Sterring Committee and Investigators of the Levosimendan Infusion Versus Dobutamine (LIPO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196–202.
Moiseyev VS, Poder P, Andrejevs N, et al; RUSSLAN Study Investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Euro Heart J. 2002;23:1422–1432.
Zairis M, Apostolatos C, Anastasiadis P, et al. The effect of a calcium sensitizer or an inotrope or none in chronic low output decompensated heart failure: Results from the calcium sensitizer or inotrope or none in low output heart failure study (CASINO). J Am Coll Cardiol. 2004;43(5 Suppl. 1):A206–A207.
Packer M. REVIVE II Trial Investigators: REVIVE II: Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. Circulation. 2005;112:3363.
Mebazaa A, Nieminen MS, Packer M, et al; SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297:1883–1891.
Nieminen MS, Cleland JG, Eha J, et al. Oral levosimendan in patients with severe chronic heart failure — the PERSIST study. Eur J Heart Fail. 2008;10:1246–1254.
Fedele F, D’Ambrosi A, Bruno N, Caria C, Brasolin B, Mancane M. Cost-effectiveness of levosimendan in patients with acute heart failure. J Cardiovasc Pharmacol. 2011;58:363–366.
Drummond M, Sculpher M, Torrance G, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005.
Oliveira MT, Jr., Follador W, Martins ML, et al. Cost analysis of the treatment of acute decompensated heart failure. Levosimendan versus dobutamine. Arq Bras Cardiol. 2005;85:9–14.
de Lissovoy G, Fraeman K, Salon J, Chay Woodward T, Sterz R. The costs of treating acute heart failure: an economic analysis of the SURVIVE trial. J Med Econ. 2008;11:415–429.
de Lissovoy G, Fraeman K, Teerlink JR, et al. Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study. Eur J Health Econ. 2010;11:185–193.
Ebner C, Hörmann C, Pölzl G, et al. Levosimendan (Simdax): A cost-effective treatment option for acute heart failure. Wiener Klinisches Magazin. 2011;2:1–4.
Signorello LB, McLaughlin JK, Lipworth L, Friis S, Sørensen HT, Blot WJ. Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Ther. 2002;9:199–205.
Italian Health Economics Association (AIES) working group. Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. PharmacoEconomics — Italian Research Articles. 2009;11:83–93.
McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: What it is and what that means. Pharmacoeconomics. 2008;26:733–744.
Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002;22:340–349.
Paletta T, Lucioni C, Volpe M. L’EuroQol (EQ-5D) per la misura dell’utilità negli studi di farmacoeconomia: Considerazioni metodologiche applicate al caso del paziente in dimissione dopo infarto miocardico. PharmacoEconomics — Italian Research Articles. 2010;12:51–59.
Author information
Authors and Affiliations
Corresponding author
Additional information
To view enhanced content go to www.advancesintherapy.com
This article is published with open access at Springerlink.com
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Lucioni, C., D’Ambrosi, A., Mazzi, S. et al. Economic Evaluation of Levosimendan Versus Dobutamine for the Treatment of Acute Heart Failure in Italy. Adv Therapy 29, 1037–1050 (2012). https://doi.org/10.1007/s12325-012-0070-4
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-012-0070-4